Advanced drug delivery reviews最新文献_第7页

Cold atmospheric plasma for gas therapy and gas-activated drug delivery 用于气体治疗和气体活化药物输送的冷大气等离子体

IF 17.6 1区医学

Advanced drug delivery reviews Pub Date : 2025-12-01 Epub Date: 2025-10-13 DOI: 10.1016/j.addr.2025.115719

Qiaoyun Li , Jaehyun Choi , Namjo Shin , Dongun Jin , Enzhen Xu , Byeongjin Ahn , Boyoung Lee , Jaiwoo Lee , Yu-Kyoung Oh

{"title":"Cold atmospheric plasma for gas therapy and gas-activated drug delivery","authors":"Qiaoyun Li , Jaehyun Choi , Namjo Shin , Dongun Jin , Enzhen Xu , Byeongjin Ahn , Boyoung Lee , Jaiwoo Lee , Yu-Kyoung Oh","doi":"10.1016/j.addr.2025.115719","DOIUrl":"10.1016/j.addr.2025.115719","url":null,"abstract":"<div><div>Cold atmospheric plasma (CAP) has emerged as a promising tool for in situ gas delivery due to its ability to generate reactive oxygen and nitrogen species, which play a crucial role in oxidative stress-mediated therapeutic effects. As the fourth state of matter, CAP is characterized by unique physicochemical properties and distinct generation mechanisms, which are discussed in terms of its fundamental principles and production techniques. This review covers current CAP delivery methods, highlighting their critical role in biomedical applications. The diverse therapeutic potential of CAP is explored, including its immunomodulatory effects in cancer therapy and its antimicrobial properties in wound healing through generation of reactive oxygen and nitrogen species. CAP also demonstrates efficacy in oral, inflammatory, gastrointestinal, and neurological conditions by eliminating biofilms, promoting tissue regeneration, and modulating immune and intracellular redox signaling pathways. Additionally, special emphasis is placed on the synergistic integration of CAP with advanced drug delivery systems to enhance therapeutic efficacy. Current challenges, potential limitations, and future directions for CAP-based biomedical applications are addressed. Despite its significant potential, challenges such as precise dose control, biological safety, and clinical translation remain unresolved. Future research should focus on optimizing CAP-based therapies, developing targeted delivery strategies, and conducting comprehensive clinical studies to facilitate its integration into mainstream medical practice.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"227 ","pages":"Article 115719"},"PeriodicalIF":17.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145283381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sonodynamic therapy: transforming sound into light for hard-to-treat tumours 声动力疗法：将声音转化为光来治疗难以治疗的肿瘤

IF 17.6 1区医学

Advanced drug delivery reviews Pub Date : 2025-11-01 Epub Date: 2025-09-12 DOI: 10.1016/j.addr.2025.115696

Paul Cressey, Shazwan Bin Abd Shukor, Maya Thanou

{"title":"Sonodynamic therapy: transforming sound into light for hard-to-treat tumours","authors":"Paul Cressey, Shazwan Bin Abd Shukor, Maya Thanou","doi":"10.1016/j.addr.2025.115696","DOIUrl":"10.1016/j.addr.2025.115696","url":null,"abstract":"<div><div>Sonodynamic therapy (SDT) is an emerging therapeutic modality against hard-to-treat tumours. It involves the use of ultrasound (US) to excite sono-sensitive moieties to produce reactive oxygen species (ROS), which induce tumour cell death. SDT employs the synergetic application of enabling chemicals named sonosensitizers and low-intensity ultrasound. Compared with photodynamic therapy, SDT has the significant advantages of deeper tissue penetration, higher accuracy, and potentially fewer adverse effects if well-designed. There are multiple suggested mechanisms for activating sonosensitizers for SDT, including sonoluminescence, pyrolysis and direct mechanical activation. However, a highly reported mechanism of action and the focus for this review is sonoluminescence (SL). SL is defined as the light generated by catastrophic implosions of oscillating bubbles in a liquid under exposure to ultrasound (US). SL has been shown to interact with sensitising molecules similar to photodynamic therapy to generate ROS. This mechanism involves delocalisation of the excited electron and subsequent transfer from excited sonosensitizers to nearby oxygen molecules (H<sub>2</sub>O and O<sub>2</sub>) in the surrounding tissues to produce ROS such as superoxides, peroxides, singlet oxygen and hydroxyl radicals. In SDT, both SL and sonosensitizers play a role in generating enough ROS to initiate the observed anticancer effects. These effects have been investigated in <em>in vitro</em>, <em>in vivo</em> and recently applied in clinical settings. There are several questions pertaining to the efficiency and safety of SDT and sonosensitizers for anticancer treatment, especially in hard-to-treat tumours, which are discussed here. Although the application of SDT has rapidly reached the clinical phase, fundamental studies are still needed to address and understand the complex mechanisms involved in the anticancer effect of SDT.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"226 ","pages":"Article 115696"},"PeriodicalIF":17.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145043386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug delivery strategies for paediatric diffuse midline gliomas 小儿弥漫性中线胶质瘤的药物递送策略

IF 17.6 1区医学

Advanced drug delivery reviews Pub Date : 2025-11-01 Epub Date: 2025-09-25 DOI: 10.1016/j.addr.2025.115695

Stefana Duca , Sara Jamshidi Parvar , Luke Kumeta , Tracey D. Bradshaw , Weng C. Chan , Felicity de Cogan , Karolina Dziemidowicz , Pavel Gershkovich , Maria Marlow , Christopher J. Morris , David Shorthouse , Andrew L. Lewis

引用次数: 0

Nitric oxide releasing graphene for next-generation therapeutics 一氧化氮释放石墨烯用于下一代治疗

IF 17.6 1区医学

Advanced drug delivery reviews Pub Date : 2025-11-01 Epub Date: 2025-08-18 DOI: 10.1016/j.addr.2025.115676

Tanveer A. Tabish , Craig A. Lygate

{"title":"Nitric oxide releasing graphene for next-generation therapeutics","authors":"Tanveer A. Tabish , Craig A. Lygate","doi":"10.1016/j.addr.2025.115676","DOIUrl":"10.1016/j.addr.2025.115676","url":null,"abstract":"<div><div>Nitric oxide (NO) is a powerful signalling molecule and plays a central role in numerous physiological processes, most notably, in the cardiovascular, immune and central nervous systems. While organic nitrates, exemplified by nitroglycerin, have been used for over a century to deliver therapeutic NO, the search for novel drugs capable of selectively increasing NO bioavailability has continued unabated. Delivery of NO is hindered by its gaseous nature, extreme reactivity, short half-life and potential for systemic toxicity. To address these challenges, controlled NO delivery systems are highly desirable, offering precise release at the site of action over defined periods. Recent advances have focused on nanoparticles for injectable or implantable use, enabling sustained, targeted NO release while degrading safely. Among these, graphene nanostructures have emerged as efficient NO carriers, since they can be specifically designed to deliver NO gas or donor compounds due to their tunable surface chemistry, easy chemical modification and good biocompatibility. In this review, we discuss the latest developments in NO-releasing graphene formulations, alongside key applications in cardiovascular diseases, antimicrobial therapy and cancer treatment.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"226 ","pages":"Article 115676"},"PeriodicalIF":17.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144899135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aptamers as a new frontier in targeted cancer therapy 适体是肿瘤靶向治疗的新前沿

IF 17.6 1区医学

Advanced drug delivery reviews Pub Date : 2025-11-01 Epub Date: 2025-09-25 DOI: 10.1016/j.addr.2025.115692

Yingying Li , Tatiana N. Zamay , Natalia A. Luzan , Evgeny A. Pryakhin , Elena V. Styazhkina , Liubov A. Osminkina , Olga S. Kolovskaya , Maya A. Dymova , Elena V. Kuligina , Vladimir A. Richter , Alena G. Bkhattachariia , Dmitry A. Bydanov , Alexander V. Galantsev , Ivan A. Vostrov , Zhenbao Liu , Galina S. Zamay , Anna S. Kichkailo , Xue-Qiang Wang

{"title":"Aptamers as a new frontier in targeted cancer therapy","authors":"Yingying Li , Tatiana N. Zamay , Natalia A. Luzan , Evgeny A. Pryakhin , Elena V. Styazhkina , Liubov A. Osminkina , Olga S. Kolovskaya , Maya A. Dymova , Elena V. Kuligina , Vladimir A. Richter , Alena G. Bkhattachariia , Dmitry A. Bydanov , Alexander V. Galantsev , Ivan A. Vostrov , Zhenbao Liu , Galina S. Zamay , Anna S. Kichkailo , Xue-Qiang Wang","doi":"10.1016/j.addr.2025.115692","DOIUrl":"10.1016/j.addr.2025.115692","url":null,"abstract":"<div><div>Cancer treatment has transitioned from traditional chemotherapy to the molecular medicine era, emphasizing personalized therapy at the molecular level. Aptamers, also known as ’chemical antibodies’, play a pivotal role in advancing molecular medicine. Utilizing the SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technique, these aptamers exhibit exceptional affinity for a wide range of targets, ranging from picomolar to nanomolar levels. Their exceptional characteristics, including ease of preparation, small size, low immunogenicity, remarkable chemical stability, and convenient modification, make them highly versatile for precise cancer therapy. Notably, aptamers have been successfully combined with therapeutic agents, such as small interfering RNAs (siRNAs), microRNAs (miRNAs), and small molecule toxins for diverse research purposes. This review article will primarily focus on recent progress in aptamer-based targeted therapy for cancer, offering readers a comprehensive insight into the latest developments in aptamer-based cancer treatment.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"226 ","pages":"Article 115692"},"PeriodicalIF":17.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145134376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovative engineering approaches to model host-microbiome interactions in vitro 体外模拟宿主-微生物相互作用的创新工程方法

IF 17.6 1区医学

Advanced drug delivery reviews Pub Date : 2025-11-01 Epub Date: 2025-09-05 DOI: 10.1016/j.addr.2025.115677

Karen M. Mancera Azamar , Samanvitha Deepthi Sudi , Zahra Mohammadalizadeh , Carleigh Coffin , Ivana K. Parker , Ana Maria Porras

{"title":"Innovative engineering approaches to model host-microbiome interactions in vitro","authors":"Karen M. Mancera Azamar , Samanvitha Deepthi Sudi , Zahra Mohammadalizadeh , Carleigh Coffin , Ivana K. Parker , Ana Maria Porras","doi":"10.1016/j.addr.2025.115677","DOIUrl":"10.1016/j.addr.2025.115677","url":null,"abstract":"<div><div>The human microbiome plays a critical role in health and disease. Disruptions in microbiota composition or function have been implicated not only as markers but also as drivers of diverse pathologies, creating opportunities for targeted microbiome interventions. Advancing these therapies requires experimental models that can unravel the complex, bidirectional interactions between human tissue and microbial communities. This scoping review examines emerging engineering approaches to design <em>in vitro</em> platforms that successfully integrate host and microbial components to model these interactions. Compared to traditional <em>in vitro</em> and <em>in vivo</em> approaches, these advanced microphysiological systems offer greater experimental control, human-specific biology, and reduced cost and ethical concerns. Here, we identify key challenges in the creation of these <em>in vitro</em> models and innovative solutions to address them by leveraging microfluidics, biomaterials, and organoid technologies, among others. These strategies have enabled the development of co-culture systems that replicate critical features of host-microbiome interfaces, including mucosal barriers, oxygen and pH gradients, mechanical stimuli, and host cell diversity. We also describe how these physiologically relevant models are uncovering new insights into epithelial-microbiota crosstalk, immune modulation by commensal microbes, and systemic effects of microbiota and their metabolites across multiple body sites. We conclude by discussing opportunities to expand these systems in scale, complexity, and clinical relevance. As these models continue to evolve, they hold the potential to transform our ability to mechanistically probe microbiome interactions, personalize therapeutic strategies, and accelerate the translation of microbiome science into clinical practice.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"226 ","pages":"Article 115677"},"PeriodicalIF":17.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144995435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug delivery, development, and technological aspects for peripheral drug eluting stents 外周药物洗脱支架的药物输送、开发和技术方面

IF 17.6 1区医学

Advanced drug delivery reviews Pub Date : 2025-11-01 Epub Date: 2025-08-29 DOI: 10.1016/j.addr.2025.115678

Sarika A. Jadhav , Ankur J. Raval , Vandana B. Patravale

{"title":"Drug delivery, development, and technological aspects for peripheral drug eluting stents","authors":"Sarika A. Jadhav , Ankur J. Raval , Vandana B. Patravale","doi":"10.1016/j.addr.2025.115678","DOIUrl":"10.1016/j.addr.2025.115678","url":null,"abstract":"<div><div>Drug-eluting stents are the standard therapy for arterial occlusions, particularly in peripheral arterial disease, owing to their efficacy in mitigating in-stent restenosis, maintaining favorable biocompatibility, and improving patient compliance. Their performance can be enhanced through the integration of particulate systems, cytostatic agents, and biodegradable polymers. The complexities associated with chronic disease progression, recurrent in-stent restenosis, the impracticality of long-term animal studies, and the absence of United States Food and Drug Administration-endorsed <em>in vitro</em> drug release protocols for peripheral drug-eluting stents underscore the need for modified strategies and accelerated <em>in vitro</em> release testing as a quality control strategy. In addition to <em>in vitro</em> drug release, other critical evaluation parameters for coated stents include coating uniformity, thickness, drug content, biodegradability, particulate matter, and sterility testing. Ethylene oxide is the most widely used method for the sterilization of drug-eluting stents. Despite their clinical significance, standardized regulatory guidelines and a unified scientific framework for stability testing remain limited. This review provides a comprehensive overview of drug delivery strategies for peripheral drug-eluting stents, coating methodologies, evaluation criteria, <em>in vitro</em> drug release and permeation studies, preclinical animal models, drug release correlations, and stability considerations, along with perspectives on future advancements and opportunities in this field.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"226 ","pages":"Article 115678"},"PeriodicalIF":17.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144915614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tumor microenvironment subtyping in pancreatic ductal adenocarcinoma: New avenues for personalized therapeutic strategies 胰腺导管腺癌的肿瘤微环境亚型：个性化治疗策略的新途径

IF 17.6 1区医学

Advanced drug delivery reviews Pub Date : 2025-11-01 Epub Date: 2025-09-12 DOI: 10.1016/j.addr.2025.115697

Dharini Srinivasan , Johann Gout , Alexander Kleger , Elodie Roger

{"title":"Tumor microenvironment subtyping in pancreatic ductal adenocarcinoma: New avenues for personalized therapeutic strategies","authors":"Dharini Srinivasan , Johann Gout , Alexander Kleger , Elodie Roger","doi":"10.1016/j.addr.2025.115697","DOIUrl":"10.1016/j.addr.2025.115697","url":null,"abstract":"<div><div>In the past decade, single-cell-resolved approaches have uncovered the extensive heterogeneity of pancreatic ductal adenocarcinoma (PDAC), reshaping our understanding of this complex solid tumor. PDAC entities exhibit both intra- and inter-tumor heterogeneity at the tumor and stromal levels, translating into distinct ecosystems and functions, ultimately impacting disease progression and treatment response. Increasing evidence highlights how specific genetic alterations drive unique tumor microenvironment landscapes, affecting fibroblast programming, immune cell contexture and extracellular matrix remodeling. In this review, we emphasize the importance of deciphering and stratifying heterogeneous tumor-stroma networks and provide an overview on the intricate crosstalk linking tumor identity and stromal phenotype. We further discuss the concept of multicellular subtyping and the role of spatial organization in shaping patient outcomes to refine prognostic and therapeutic stratification. Lastly, we explore existing and potential therapeutic strategies aimed at targeting both tumor-intrinsic and stromal-extrinsic vulnerabilities, offering insights into approaches that could enhance the efficacy of tailored treatment schemes. By integrating these perspectives, we aim to provide a comprehensive framework for advancing precision medicine in PDAC.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"226 ","pages":"Article 115697"},"PeriodicalIF":17.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145043168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aptamer-based targeted drug delivery and disease therapy in preclinical and clinical applications 基于适体体的靶向药物传递和疾病治疗在临床前和临床应用

IF 17.6 1区医学

Advanced drug delivery reviews Pub Date : 2025-11-01 Epub Date: 2025-08-29 DOI: 10.1016/j.addr.2025.115680

Weihong Yang , Chunyan Ran , Xinran Lian , Zehua Wang , Zhen Du , Tao Bing , Yu Zhang , Weihong Tan

{"title":"Aptamer-based targeted drug delivery and disease therapy in preclinical and clinical applications","authors":"Weihong Yang , Chunyan Ran , Xinran Lian , Zehua Wang , Zhen Du , Tao Bing , Yu Zhang , Weihong Tan","doi":"10.1016/j.addr.2025.115680","DOIUrl":"10.1016/j.addr.2025.115680","url":null,"abstract":"<div><div>The advent of precision medicine has created an urgent need for advanced drug-targeting strategies and refined drug delivery systems. Aptamers, characterized by their exceptional affinity and specificity, low molecular weight, negligible immunogenicity, remarkable stability, cost-effectiveness, and structural versatility, are emerging as promising candidates in targeted therapeutics, both in preclinical research and clinical applications. This review provides a comprehensive analysis of the latest advancements in aptamer-based therapeutic strategies, encompassing three key application domains: direct therapeutic agents, targeted ligand engineering, and controlled drug release. We will summarize the preclinical applications of aptamers for various disease therapies, including eye disorders, cancers, coagulation, and inflammation. Particular emphasis is placed on emerging clinical-stage aptamer therapeutics undergoing rigorous evaluation for these diseases. Furthermore, we will discuss the potential challenges and unlimited opportunities for the clinical transformation and commercialization of aptamers.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"226 ","pages":"Article 115680"},"PeriodicalIF":17.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144919189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optical technologies in monitoring mobility and delivery of drugs and metabolic agents1 光学技术在监测药物和代谢剂的流动性和输送

IF 17.6 1区医学

Advanced drug delivery reviews Pub Date : 2025-11-01 Epub Date: 2025-09-26 DOI: 10.1016/j.addr.2025.115699

Valery V. Tuchin , Tianhong Dai , Luís M. Oliveira

引用次数: 0